EV Biologics (EV Biologics) Accounts Receivable : $1.03 Mil (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. EV Biologics's accounts receivables for the quarter that ended in Dec. 2017 was $1.03 Mil.

Accounts receivable can be measured by Days Sales Outstanding. EV Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2017 was 2.43.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. EV Biologics's Net-Net Working Capital per share for the quarter that ended in Dec. 2017 was $-3.11.

EV Biologics Accounts Receivable Historical Data

The historical data trend for EV Biologics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Accounts Receivable Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Accounts Receivable

3.96

5.18

9.33

5.73

4.97

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Accounts Receivable	Get a 7-Day Free Trial												5.73	4.92	4.53	4.97	1.03

EV Biologics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

EV Biologics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

EV Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.032	/	38.723	*	91
=	2.43

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), EV Biologics's accounts receivable are only considered to be worth 75% of book value:

EV Biologics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2017 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(8.387	+	0.75 * 1.032	+	0.5 * 0.125	-	16.719
-	0	-	0)	/	2.41107
=	-3.11

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

EV Biologics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of EV Biologics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Accounts Receivable

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3